Lupin to develop inhalers with near-zero global warming potential propellants
Sustainability

Lupin to develop inhalers with near-zero global warming potential propellants

Lupin's R&D teams are working on products with a near-zero global warming potential propellant

  • By IPP Bureau | November 01, 2024

Global pharma major Lupin Limited announced its focus on formulating respiratory inhalers by incorporating a propellant with near-zero global warming potential (GWP). This initiative aims to provide patients with pressurised metered dose inhalers (pMDIs) that maintain the same efficacy and safety, while significantly reducing their environmental impact. This is aligned to the regulations in Europe and Lupin’s commitment to reducing its carbon footprint. 

Richard Dekhuijzen, Professor of Pulmonology at the Radboud University Medical Center in Nijmegen, the Netherland said, “The development of inhalers with near-zero global warming potential serves two major objectives: firstly, a maximal reduction of their environmental impact, and secondly, as important, keeping these medications available for those patients who really need these type of inhalers since they are unable to use dry powder inhalers.”

Vinita Gupta, Chief Executive Officer, Lupin said, “We are committed to making a positive impact in the lives of asthma patients worldwide. Our focus is on patient-centric sustainable healthcare innovation, ensuring that those who receive our pMDIs have reliable access to effective treatments with minimal impact to the environment.”         

Upcoming E-conference

Other Related stories

Startup

Digitization